Cowen & Co. Maintains a Buy Rating on Adverum Biotechnologies (ADVM)

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Adverum Biotechnologies (ADVM) yesterday. The company’s shares closed yesterday at $3.74.

According to, Nadeau is a 5-star analyst with an average return of 8.7% and a 50.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Allogene Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adverum Biotechnologies with a $5.13 average price target, implying a 37.2% upside from current levels. In a report issued on November 2, Piper Jaffray also maintained a Buy rating on the stock with a $8 price target.


See today’s analyst top recommended stocks >>

Based on Adverum Biotechnologies’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $18.81 million. In comparison, last year the company had a GAAP net loss of $13.83 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich’s ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

From Our Partners